Mode
Text Size
Log in / Sign up
Phase 1 Completed N=24 Basic Science

Pharmacokinetic Study Of AGILE AG200-15 After Weekly Application Under Various Conditions in Healthy Female Volunteers

Healthy
Source: ClinicalTrials.gov NCT01375946 ↗
Enrolled (actual)
24
Serious AEs
0.0%
Results posted
Dec 2017
Primary outcomePrimary: Area Under the Concentration Versus Time Curve (AUC) (0-168) Profile of Levonorgestrel (LNG) — 157; 118; 153; 137 ng*hr/mL

Summary

A study to evaluate pharmacokinetic profile, wearability and safety of AG200-15, transdermal delivery of levonorgestrel (LNG) and ethinyl estradiol (EE), under normal conditions and external conditions of heat, humidity, cold water and exercise.

Outcome Measures

OutcomeResultp-value
PRIMARY
Area Under the Concentration Versus Time Curve (AUC) (0-168) Profile of Levonorgestrel (LNG)
157; 118; 153; 137; 119
PRIMARY
AUC(0-168) Profile of Ethinyl Estradiol (EE)
4.7; 4.3; 4.9; 4.3; 3.9
PRIMARY
Steady-state Concentration (Css) (48-168) Profile of LNG
1068; 793; 1033; 918; 814
PRIMARY
Css (48-168) Profile of EE
30; 28; 29; 27; 24
SECONDARY
Patch Adhesion
0.08; 0.08; 0; 0; 0.17

Eligibility Criteria

Inclusion Criteria

  • Healthy women, ages 18-45
  • Body mass index (BMI)of ≥18 and less than or equal to 32, and weight ≥ 110 lbs.
  • Willing to use a non-hormonal method of contraception if of childbearing potential, or have already undergone previous bilateral tubal ligation or hysterectomy
  • Willing to refrain from use of alcohol and grapefruit juice from 48 hours prior to patch application until completion of each treatment period
  • Willing to give informed consent to participate in study

Exclusion Criteria

  • Known or suspected pregnancy
  • Breast-feeding or within 1 month after stopping breast-feeding
  • Smokers
  • Any disease that may worsen with hormonal treatment
  • Hypersensitivity to transdermal preparations or sensitivity to surgical/medical tape
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01375946). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search